Evidence map›Paper›PMID 36341686›Full record

ArticleCancer medicine2023

The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancer.

Chenglong Zhao, Jianghua Li, Yongchang Zhang, Rui Han, Yubo Wang, Li Li, Yimin Zhang, Mengxiao Zhu, Jie Zheng, Haiwei Du and 5 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Chenglong ZhaoDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Jianghua LiDepartment of Intensive care unit, Daping Hospital, Army Medical University, Chongqing, China.
Yongchang ZhangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.ORCID 0000-0002-6829-7176
Rui HanDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Yubo WangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Li LiDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Yimin ZhangDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Mengxiao ZhuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Jie ZhengDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Haiwei DuBurning Rock Biotech, Guangzhou, China.
Chen HuDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
Chengzhi ZhouRespiratory Medicine Department, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0003-0029-6879
Nong YangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Shangli CaiBurning Rock Biotech, Guangzhou, China.
Yong HeDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.ORCID 0000-0003-4123-894X
Army Medical University · CNCentral South University · CNBurning Rock Biotech (China) · CNFirst Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasma and tissue biopsy have both used for targeting actionable driver gene mutations in lung cancer, whose concordance is imperfect. A reliable method to predict the concordance is urgently needed to ease clinical application.

methodsA total of 1012 plasma samples, including 519 with paired-tissue biopsy samples, derived from lung adenocarcinoma patients were retrospectively enrolled. We assessed the associations of several clinicopathological characteristics and serum tumor markers with the concordance between plasma and tissue biopsies.

resultsWhen carcinoembryonic antigen (CEA) levels were higher than thresholds of 15.01 ng/ml and 51.15 ng/ml, the positive predictive value of concordance reached 90% and 95%, respectively. When CEA levels were lower than thresholds of 5.19 ng/ml and 3.26 ng/mL, the negative predictive value of concordance reached 45% and 50%. The performance of CYFRA21-1 in predicting concordance was similar but inferior to CEA (AUC: 0.727 vs. 0.741, p = 0.633). The performance of CEA combined with CYFRA21-1 in predicting the concordance was similar to that of the combination of independent factors derived from the LASSO regression model (AUC: 0.796 vs. 0.818, p = 0.067). CEA (r = 0.47, p < 0.01) and CYFRA21-1 levels (r = 0.45, p < 0.05) were significantly correlated with the maximum variant allele frequency, respectively.

conclusionsCEA combined with CYFRA21-1 could effectively predict the concordance between plasma and tissue biopsies, which could be used for evaluating the priority of plasma and tissue biopsies for gene testing to timely guide clinical applications in advanced lung adenocarcinoma patients.

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsAntigens, NeoplasmBiomarkers, TumorCarcinoembryonic AntigenHigh-Throughput Nucleotide SequencingHumansKeratin-19Liquid BiopsyRetrospective Studiesantigen CYFRA21.1Antigens, NeoplasmBiomarkers, TumorCarcinoembryonic AntigenKeratin-19circulating tumor DNAliquid biopsynext generation sequencingnon-small cell lung cancerserum tumor marker

Identifiers

PMID36341686
PMCPMC10028052
OpenAlexW4308370550

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read57
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.